Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry DOI Creative Commons

Manaswini Pillai,

Simon Erridge,

Lara Bapir

et al.

Expert Review of Neurotherapeutics, Journal Year: 2022, Volume and Issue: 22(11-12), P. 1009 - 1018

Published: Nov. 2, 2022

Background The current paucity of clinical evidence limits the use cannabis-based medicinal products (CBMPs) in post-traumatic stress disorder (PTSD). This study investigates health-related quality life (HRQoL) changes and adverse events patients prescribed CBMPs for PTSD.Methods A case-series from UK Medical Cannabis Registry was analyzed. HRQoL assessed at 1-, 3-, 6-months using validated patient reported outcome measures (PROMs). Adverse were analyzed according to Common Terminology Criteria Events version 4.0. Statistical significance defined as p < 0.050.Results Of 162 included patients, 88.89% (n = 144) current/previous cannabis users. Median daily CBMP dosages 5.00 (IQR: 0.00–70.00) mg cannabidiol 145.00 100.00–200.00) Δ9-tetrahydrocannabinol. Significant improvements observed PTSD symptoms, sleep, anxiety across all follow-up periods (p 0.050). There 220 (135.8%) by 33 (20.37%), with majority graded mild or moderate severity 190, 117.28%). Insomnia fatigue had greatest incidence 20, 12.35%).Conclusions Associated who initiated therapy. analysis suggests acceptability safety up 6 months. may inform randomized placebo-controlled trials, required confirm causality determine optimal dosing.

Language: Английский

Exploring the Anxiolytic, Antidepressant, and Immunomodulatory Effects of Cannabidiol in Acute Stress Rat Models DOI Creative Commons
H. Zlatanova, Maria Georgieva-Kotetarova, N. Vilmosh

et al.

Applied Biosciences, Journal Year: 2025, Volume and Issue: 4(1), P. 4 - 4

Published: Jan. 21, 2025

Cannabidiol (CBD), a non-psychoactive compound derived from Cannabis sativa, is believed to have anxiety-reducing and antidepressant effects. However, existing data are inconsistent, likely due variations in experimental designs, dosages, stress models. This study sought assess the impact of CBD on anxiety depression-like behaviors Wistar rats exposed acute cold stress, as well its pro- anti-inflammatory cytokines. Male were treated with (2.5, 5, or 10 mg/kg) vehicle for 14 days subjected behavioral tests, including elevated plus maze, social interaction, forced swim tests. Serum levels cytokines (IL-6, TNF-α, IL-1β, IL-10) analyzed post-experiment using ELISA. Results demonstrated dose-dependent anxiolytic effect CBD, significant improvements interaction reductions anxiety-like at 5 mg/kg. All doses decreased immobility test, suggesting Furthermore, selectively lowered IL-6 levels, key cytokine depression pathogenesis. These findings indicate that has properties, partially mediated by modulation inflammatory processes, particularly IL-6.

Language: Английский

Citations

2
Pharmacological effects of cannabidiol by transient receptor potential channels DOI
Leila Etemad, Gholamreza Karimi, Mohaddeseh Sadat Alavi

et al.

Life Sciences, Journal Year: 2022, Volume and Issue: 300, P. 120582 - 120582

Published: April 25, 2022

Language: Английский

Citations

45
Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial DOI Creative Commons
Estácio Amaro da Silva Júnior, Wandersonia Moreira Brito Medeiros,

João Paulo Mendes dos Santos

et al.

Trends in Psychiatry and Psychotherapy, Journal Year: 2022, Volume and Issue: unknown

Published: May 26, 2022

Autism spectrum disorder (ASD) is characterized by persistent deficits in social communication and interaction restricted repetitive patterns of behavior. Some studies have shown that substances derived from Cannabis sativa improve the quality life children with ASD without causing serious adverse effects, thus providing an alternative therapeutic option. The objective this study was to evaluate efficacy safety a cannabis extract rich cannabidiol (CBD) ASD.

Language: Английский

Citations

39
Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder DOI Creative Commons
Nicolas Singewald, Simone B. Sartori, Andreas Reif

et al.

Neuropharmacology, Journal Year: 2023, Volume and Issue: 226, P. 109418 - 109418

Published: Jan. 6, 2023

Psychiatric disorders associated with psychological trauma, stress and anxiety are a highly prevalent increasing cause of morbidity worldwide. Current therapeutic approaches, including medication, effective in alleviating symptoms posttraumatic disorder (PTSD), at least some individuals, but have unwanted side-effects do not resolve underlying pathophysiology. After period stagnation, there is renewed enthusiasm from public, academic commercial parties designing developing drug treatments for these disorders. Here, we aim to provide snapshot the current state this field that written neuropharmacologists, also practicing clinicians interested lay-reader. introducing currently available treatments, summarize recent/ongoing clinical assessment novel medicines PTSD, grouped according primary neurochemical targets their potential produce acute and/or enduring effects. The evaluation putative targeting monoamine (including psychedelics), GABA, glutamate, cannabinoid, cholinergic neuropeptide systems, amongst others, discussed. We emphasize importance clinically assessing new medications based on firm understanding neurobiology stemming rapid advances being made neuroscience. This includes harnessing neuroplasticity bring about lasting beneficial changes brain rather than – as many transient attenuation symptoms, exemplified by combining psychotropic/cognitive enhancing drugs psychotherapeutic approaches. conclude noting other emerging trends promising phase development.

Language: Английский

Citations

38
Cannabidiol goes nuclear: The role of PPARγ DOI

Sara Khosropoor,

Mohaddeseh Sadat Alavi, Leila Etemad

et al.

Phytomedicine, Journal Year: 2023, Volume and Issue: 114, P. 154771 - 154771

Published: March 15, 2023

Language: Английский

Citations

29
Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review DOI Creative Commons
Kuldeep Singh, Bharat Bhushan, Dilip Kumar Chanchal

et al.

Behavioural Neurology, Journal Year: 2023, Volume and Issue: 2023, P. 1 - 17

Published: Oct. 12, 2023

Cannabidiol (CBD), derived from Cannabis sativa, has gained remarkable attention for its potential therapeutic applications. This thorough analysis explores the increasing significance of CBD in treating neurological conditions including epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's which present major healthcare concerns on a worldwide scale. Despite lack available therapies, been shown to possess variety pharmacological effects preclinical clinical studies, making it an intriguing competitor. review brings together most recent findings endocannabinoid neurotransmitter systems, as well anti-inflammatory pathways, that underlie CBD's modes action. Synthesized efficacy safety assessments range illnesses are included, covering human trials, vitro animal models. The investigation includes how could protect neurons, control neuroinflammation, fend off oxidative stress, manage neuronal excitability. study emphasizes existing studies future possibilities research, addressing research issues such regulatory complications contradicting results, advocates further ideal dose methodologies. By emphasizing improve patient well-being, this presents revised viewpoint suitability intervention illnesses.

Language: Английский

Citations

23
Novel rapid treatment options for adolescent depression DOI Creative Commons
Sandra Ledesma‐Corvi, Jordi Jornet-Plaza, Laura Gálvez‐Melero

et al.

Pharmacological Research, Journal Year: 2024, Volume and Issue: 201, P. 107085 - 107085

Published: Feb. 2, 2024

There is an urgent need for novel fast-acting antidepressants adolescent treatment-resistant depression and/or suicidal risk, since the selective serotonin reuptake inhibitors that are clinically approved age (i.e., fluoxetine or escitalopram) take weeks to work. In this context, one of main research lines our group characterize at preclinical level approaches rapid-acting adolescence. The present review summarizes potential use in adolescence non-pharmacological options, such as neuromodulators (electroconvulsive therapy and other innovative types brain stimulation), well pharmacological including consciousness-altering drugs (mainly ketamine but also classical psychedelics) cannabinoids cannabidiol), with promising responses. Following a brief analytical explanation depression, we general introduction each therapeutical approach together clinical evidence supporting its beneficial extrapolated from prior successful examples adults), then report recent ongoing studies will aid improving inclusion these therapies clinic, by considering sex-, age-, dose-related differences, factors might affect efficacy long-term safety. Finally, conclude providing future avenues maximize treatment response, more importance designing testing options safe depression.

Language: Английский

Citations

9
CBD and the 5-HT1A receptor: A medicinal and pharmacological review DOI

Claire Alexander,

Jiyoon Jeon,

Kyle Nickerson

et al.

Biochemical Pharmacology, Journal Year: 2025, Volume and Issue: 233, P. 116742 - 116742

Published: Jan. 6, 2025

Language: Английский

Citations

1
Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial DOI Creative Commons
Mary Kathryn Dahlgren, Ashley M. Lambros, Rosemary T. Smith

et al.

Communications Medicine, Journal Year: 2022, Volume and Issue: 2(1)

Published: Nov. 2, 2022

Abstract Background Evidence suggests cannabidiol (CBD) has anxiolytic properties, indicating potential for novel treatment strategies. However, few clinical trials of CBD-based products have been conducted, and none thus far examined the impact these on cognition. Methods For open-label stage trial NCT02548559, autoregressive linear modeling assessed efficacy tolerability four-weeks 1 mL t.i.d. with a full-spectrum, high-CBD sublingual solution (9.97 mg/mL CBD, 0.23 Δ−9-tetrahydrocannabinol) in 14 outpatients moderate-to-severe anxiety, defined as ≥16 Beck Anxiety Inventory (BAI) or ≥11 Overall Severity Impairment Scale (OASIS). Results Findings suggest significant improvement primary outcomes measuring anxiety secondary assessing mood, sleep, quality life, cognition (specifically executive function) following treatment. is significantly reduced at week 4 relative to baseline (BAI: 95% CI = [−21.03, −11.40], p < 0.001, OASIS: [−9.79, −6.07], 0.001). Clinically response (≥15% symptom reduction) achieved maintained early most patients (BAI 78.6%, OASIS 92.7%); cumulative frequency responders reached 100% by 3. The study drug well-tolerated, high adherence/patient retention no reported intoxication serious adverse events. Minor side effects, including sleepiness/fatigue, increased energy, dry mouth are infrequently endorsed. Conclusions provide preliminary evidence supporting product anxiety. Patients quickly achieve maintain reduction effects. A definitive assessment this symptoms will be ascertained ongoing double-blind, placebo-controlled stage.

Language: Английский

Citations

31
Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications DOI
Srushti Tambe, Suraj N. Mali, Purnima Amin

et al.

Journal of Integrative Medicine, Journal Year: 2023, Volume and Issue: 21(3), P. 236 - 244

Published: March 18, 2023

Language: Английский

Citations

17